BICALUTAMIDE 150 MG MAINTAINS BONE MINERAL DENSITY DURING MONOTHERAPY FOR LOCALIZED OR LOCALLY ADVANCED PROSTATE CANCER
Abstract
Purpose:
We evaluated changes in bone mineral density (BMD), fat-free mass (FFM) and serum lipid levels during bicalutamide 150 mg monotherapy compared with medical castration for 2 years.
Materials and Methods:
A total of 103 men with localized or locally advanced prostate cancer (T1–T4, Nx, M0) for whom immediate androgen deprivation was indicated were enrolled in this prospective, multicenter, open-label, parallel group study. Patients were randomized to bicalutamide 150 mg once daily (51) or medical castration with a luteinizing hormone releasing hormone analogue (52) for 96 weeks. Primary end points were mean percent change from baseline in lumbar spine BMD, hip BMD and FFM at 96 weeks. Mean changes in lipid parameters with time were also evaluated.
Results:
BMD was maintained during bicalutamide 150 mg monotherapy (+2.42% for lumbar spine BMD and +1.13% for hip BMD at week 96), while castration was associated with a progressive loss in BMD (−5.40% and −4.39% at week 96, respectively, both p <0.0001 at week 96). There was no significant difference between bicalutamide 150 mg and castration in mean percent change from baseline in FFM (−1.56% and −3.86%, respectively, at week 96, p = 0.31), although there was a trend for greater progressive loss over time with castration. Mean changes in lipid parameters were small and similar in the 2 groups.
Conclusions:
Bicalutamide 150 mg monotherapy may offer an important advantage compared to castration in terms of bone loss and body composition for patients who require long-term androgen deprivation for localized or locally advanced prostate cancer.
References
- 1 : Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol2002; 167: 2361. Link, Google Scholar
- 2 : Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol2000; 163: 181. Link, Google Scholar
- 3 : Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol1999; 161: 1219. Link, Google Scholar
- 4 : Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer. BJU Int2000; 86: 449. Google Scholar
- 5 : Osteoporosis after orchiectomy for prostate cancer. J Urol1997; 157: 439. Link, Google Scholar
- 6 : Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol2002; 56: 779. Google Scholar
- 7 : Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab2002; 87: 599. Crossref, Medline, Google Scholar
- 8 : The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab2001; 86: 4261. Crossref, Medline, Google Scholar
- 9 : Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab2001; 86: 2787. Google Scholar
- 10 : Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab2001; 281: E1172. Google Scholar
- 11 : Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol2000; 164: 1579. Link, Google Scholar
- 12 : Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. J Urol2002; 168: 429. Link, Google Scholar
- 13 : Endocrine profiles during administration of the new non-steroidal anti-androgen Casodex in prostate cancer. Clin Endocrinol (Oxf)1994; 41: 525. Google Scholar
- 14 : The non-steroidal antiandrogen, bicalutamide (‘Casodex’), may preserve bone mineral density as compared with castration: results of a preliminary study. World J Urol2003; 21: 37. Google Scholar
- 15 : Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer. Urology2003; 61: 127. Google Scholar
- 16 : Effect of antiandrogens casodex and epitestosterone on bone composition in mice. Bone1997; 20: 473. Google Scholar
- 17 : Bicalutamide (Casodex) treatment does not produce bone effects in male Wistar rats. J Bone Min Res1999; 14: S220. abstract F034. Google Scholar
- 18 : A clinical study of decreased bone density in the patients treated with long-term luteinizing hormone releasing hormone analogue (LHRH-a)—the risk of iatrogenic osteoporosis due to treatment of carcinoma of prostate. Nippon Hinyokika Gakkai Zasshi1998; 89: 961. Google Scholar
- 19 : Loss of lean body and muscle mass correlates with androgen levels in hypogonadal men with acquired immunodeficiency syndrome and wasting. J Clin Endocrinol Metab1996; 81: 4051. Google Scholar
- 20 : Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. J Urol2000; 163: 1743. Link, Google Scholar
From the Urological Associates of Lancaster Ltd, Lancaster, Pennsylvania, Urological Physicians of San Diego, San Diego, California, Michigan Medical Urology, Grand Rapids, Michigan, and AstraZeneca, Wilmington, Delaware
